ExodusPoint Capital Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

ExodusPoint Capital Management’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$75K	Sell	24,419 -92,907	-79%	-$285K	﹤0.01%	1450
2025 Q4	$418K	Buy	117,326 +2,083	+2%	+$7.72K	﹤0.01%	1216
2025 Q3	$402K	Buy	+115,243	New	+$395K	﹤0.01%	1235
2022 Q2	–	Sell	-106,505	Closed	-$759K	–	2454
2022 Q1	$759K	Buy	106,505 +75,805	+247%	+$511K	0.01%	1308
2021 Q4	$299K	Buy	+30,700	New	+$273K	﹤0.01%	1657

Other funds holding STLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ExodusPoint Capital Management's STLN Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 79% in Q1 2026, selling an estimated $285K and leaving 24,419 shares worth $75K. The position accounts for ﹤0.01% of the portfolio, ranked #1450.

ExodusPoint Capital Management first reported a position in STLN in Q4 2021 and has held it in 5 quarters since. The position peaked at $759K in Q1 2022. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

ExodusPoint Capital Management held 24,419 shares of Starling Oncology Institute, Inc. Common Stock worth $75K as of Q1 2026.
ExodusPoint Capital Management sold 92,907 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $285K.
Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1450 holding.
ExodusPoint Capital Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2021 and has held it in 5 quarters since.
ExodusPoint Capital Management's Starling Oncology Institute, Inc. Common Stock position peaked at $759K in Q1 2022.
115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.